Innovations and Emerging Technologies in the Regulated Environment of Pharma Effective training programs are essential for maintaining compliance, improving operational efficiency, and ensuring data ...

Harness the Power of AI in GxP – East 2026 brings together industry leaders, innovators, and compliance professionals to explore the evolving role of Artificial Intelligence in regulated life sciences ...

MAiGRATE — part of CLAiRE AI Agentic Platform — automates the most complex and risky part of any platform transition: moving regulated data from legacy systems to modern platforms. Automated ingestion ...

Speak with one of our AI compliance experts and find out how Compliance Group can help your organization adopt and validate AI with confidence.

In regulated environments across the pharmaceutical, MedTech, and biotechnology sectors where AI, data integrity has traditionally evaluated through presence, completeness, and traceability of ...

One platform that never stops watching. Most compliance programs respond to problems. CLAiRE prevents them — with AI agents running continuously across every high-risk domain, from AI governance and ...

Most staffing firms send bodies. We send domain-vetted life sciences specialists—CSA validators, QA leads, Polarion engineers, and Veeva admins who know GxP, not just coding or project management.

For quality leaders navigating FDA’s CSA guidance, AI governance requirements, and the pressure to modernize without breaking compliance—this is the guide that ...

Score your AI governance and validation readiness across five dimensions in 5 minutes. Get an instant maturity rating and next steps, built to ISO/IEC 42001.

AI agents that layer on top of the quality infrastructure you already have—no rip-and-replace required. Just intelligence where your current system goes blind. You invested in an enterprise Quality ...

Deploying AI in regulated environments without a governance framework is not a technology risk. It is a regulatory and reputational risk—and the FDA is already asking about it. Imagine this scenario: ...

The biggest quality management decision your company will make is not which legacy QMS to buy. It’s whether to buy one at all. You run quality at a growing biotech. You’ve moved past the “spreadsheets ...